RNAZ logo

RNAZ
TransCode Therapeutics Inc

7,476
Mkt Cap
$10.95M
Volume
8,467.00
52W High
$614.41
52W Low
$6.15
PE Ratio
-0.03
RNAZ Fundamentals
Price
$13.77
Prev Close
$13.14
Open
$13.32
50D MA
$11.51
Beta
1.80
Avg. Volume
12,028.71
EPS (Annual)
-$1,317.38
P/B
1.78
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO TransCode Therapeutics presents preliminary data from its completed...
PR Newswire·10d ago
News Placeholder
More News
News Placeholder
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset
The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial.
Stocktwits·16d ago
News Placeholder
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside
TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.
Stocktwits·6mo ago
News Placeholder
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. Announces Results of Special Meeting TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025...
PR Newswire·8mo ago
News Placeholder
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead...
PR Newswire·9mo ago
News Placeholder
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and...
PR Newswire·9mo ago
News Placeholder
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead...
PR Newswire·9mo ago
News Placeholder
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing...
PR Newswire·10mo ago
News Placeholder
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial TransCode Therapeutics...
PR Newswire·10mo ago
News Placeholder
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. read more...
Benzinga·1y ago

Latest RNAZ News

View

Advertisement|Remove ads.

Advertisement|Remove ads.